report non-gaap ep vs revenu y/
vs comfort consensu unfortun guidanc
expect particularli low end investor debat sustain
franchis suspect guid increas fear despit track record
product sale y/i consensu grew solid clip
y/i declin legaci franchis off-set growth newer fact
product portfolio beat consensu expect quarter sever
y/i vs aranesp y/i vs declin somewhat
slower project higher growth franchis includ repatha
y/i vs prolia y/i vs xgeva
y/i vs grew faster expect out-performance drove substanti
beat total revenu y/i vs consensu expens save sg
sale vs estim sale tax rate vs
brought non-gaap ep y/i vs consensu estim
revenu guidanc put consensu y/i high
end expect similarli non-gaap ep guidanc prior
street consensu wider normal rang revenu ep guidanc
due consider potenti impact competit threat sever legaci
product includ primarili possibl launch gener sensipar appeal decis
anticip around mid-year also impact current neulasta biosimilar
potenti launch addit guid expect net
sell price across portfolio declin mid-singl digit percentag vs
declin epogen aranesp greater compar
enbrel declin similar amount partial compens fall revenu opex
expect flat rel driven cost save sg launch
expens subsid off-set partli increas expenditur invest
early-stag pipelin adjust estim consist total revenu
estim cut non-gaap ep estim
biosimilar competit g-csf esa franchis
sale neulasta/neupogen y/i vs beat expect due partli
purchas neulasta barda neulasta maintain share long-
act market though fulphila launch like hamper suppli issu
coheru udenyca launch januari market use
onpro devic confid abil defend share though
anticip revenu europ declin y/i cut neulasta/
estimate y/i y/i epogen y/
vs aranesp y/i vs readili beat consensu
face competit retacrit launch novemb
expect signific deterior net price epogen aranesp
revenu declin faster contract
pleas see page report import disclosur
think under-valued anticip long term cash flow
fundament back biolog franchis good longev superior geograph
spend reason pipelin trade discount pharma peer
think downsid share limit said also overli enthusiast
prospect legaci product drive product revenu
face new competit and/or price pressur question
whether declin quickli opinion substanti out-performance
requir investor gain confid abil newer product pipelin
off-set declin increas overal product sale
phase ii data antibodi
migrain prevent
district court decis enbrel patent
infring suit sandoz
data phase studi kra inhibitor
ep growth
price-to-earnings ratio expand toward
revenu growth greater
pipelin contribut substanti
valu model
biosimilar launch exceed
revenu growth lower project
price-to-earnings ratio pharma group undergo
fail rais dividend pursu
among world largest biotechnolog compani product sale
approxim revenu deriv biolog
unlik experi gener competit forese futur major brand includ
enbrel sale neupogen/neulasta denosumab franchis brand
xgeva cancer prolia osteoporosi sale aranesp/epogen
amgen continu invest six therapeut area focu leverag
genet capabl decod databas within portfolio newer product
favor repatha antibodi signific potenti treat sever
hypercholesterolemia aimovig migrain prevent burgeon oncolog
aimovig continu strong launch vs consensu sale
aimovig benefit chang prior period account estim due
higher averag net sell price vs prior estim disclos
patient start sinc launch insur access improv
patient gone commerci drug prescript paid
vs guid short-term step-down
net sell price aimovig new contract agreement come place
begin year aimovig maintain statu market lead anti-cgrp
prescript share end though long-term benefit first-
mover advantag bear watch face strong launch two competitor
clinic stage market oncolog candid last night manag
disclos data either expect possibl program
includ bcma hle-bit multipl myeloma kra
inhibitor solid tumor
though result strong suspect guidanc pressur
stock investor debat sustain legaci product
guidanc particularli low end like exacerb fear
underwhelm guidanc overli concern histor
guid conserv suspect absent major disappoint
guidanc ratchet said also overli
enthusiast prospect think somewhat under-valued
expect long-term cash flow legaci product drive
product revenu face new competit and/or price pressur
question whether declin quickli substanti out-performance
possibl opinion investor gain confid abil
newer product pipelin off-set declin increas overal product sale
far result mix aimovig earli trend promis
potenti captur substanti share larg lucr migrain market though
impact compet launch aimovig side effect profil must watch
undertaken substanti effort improv access repatha come
expens much lower price oncolog pipelin emerg thu far
candid remain unproven order multipl expand meaning
think newer franchis must appear capabl drive meaning top-lin
growth absent stock like track ep project growth period
among world largest biotechnolog compani product sale
y/i deriv revenu superior
market drug price moreov approxim revenu deriv
biolog unlik experi substitut competit
forese futur major brand includ enbrel sale
neupogen/neulasta xgeva/prolia denosumab aranesp/epogen
recent complet seri restructur expand
oper margin commit return cash
sharehold form dividend stock buyback expect share
outperform compani increas dividend post upsid consensu revenu
ep expect receiv credit newer product repatha
aimovig model non-gaap ep growth commit
aggress share repurchas plan boost ep growth near
cog percent sale
 percent sale
sg percent sale
compani report cowen compani
phase ii data antibodi migrain prevent
phase data inhibitor solid tumor patient
district court decis enbrel patent infring suit sandoz
launch mvasi abp biosimilar avastin europ
potenti launch gener sensipar new gener sensipar settlement
potenti launch addit neulasta biosimilar
possibl eu approv decis even romosozumab postmenopaus osteoporosi
potenti regulatori decis fda ema abp biosimilar infliximab
potenti regulatori decis fda kanjinti biosimilar trastuzumab
phase data abp biosimilar rituximab nhl
initi phase trial abp biosimilar eculizumab pnh
data phase candor studi kyproli dexamethason darzalez r/r mm
pipelin updat bite program mm aml nhl glioblastoma
pipelin updat oral iv inhibitor mm aml
phase data lipoprotein sirna patient elev lp
cowen compani
cowen compani
growth growth aranesp y/i erythropoietin enbrel growth sale g-csf growth dmab growth kyproli growth product sale growth revenu growth good sold margin develop margin product incom growth growth share outstand cowen
cowen compani
 aranesp y/i erythropoietin enbrel growth sale g-csf growth dmab growth kyproli growth product sale growth revenu growth good sold margin develop loss affili margin product incom growth share outstand ep exclud fasb abp stock compens expens merger-rel item ep cowen
cowen compani
oper activitiesnet acquir in-process d- depreci base compens defer incom taxes- pp impairments- chang work capit less inventories- provid oper invest activ purchas /sale /proce market securities- other- net use invest financ activitiesproce issuanc common common stock- other- net provid financ cash cash cash equival begin cash equival end summari oper exclud non-recur item cowen
calcul target price employ one valuat methodolog
includ discount earn analysi discount cash flow analysi net present
valu analysi and/or compar compani analysi analys may may
requir use object measur price-to-earn price-to-sal multipl
well subject measur discount rate
make invest recommend earli stage pre-commerci biotechnolog
compani base upon assess technolog probabl pipelin
success potenti market opportun event success howev
compani lack tradit financi metric believ good
methodolog assign specif target price stock
multipl risk inher invest biotechnolog sector
beyond system risk also clinic regulatori commerci risk addit
biotechnolog compani requir signific amount capit order develop
clinic program capital-rais environ alway chang risk
necessari capit complet develop may readili avail
base busi compris mostli older biolog could experi biosimilar
competit impact difficult ass paid reason
sum acquir lead candid kyproli drug uncertain
sale potenti manag outlin strategi return cash sharehold
deviat plan could creat stock weak volatil much perceiv
valu within pipelin focus anti-cgrp anti-sclerostin
associ regulatori commerci risk
